Ergomed Signs Co-Development Collaboration Agreement with Genzyme Corporation to Develop Tasidotin in Oncology
Ergomed announced that it has signed an agreement with Genzyme Corporation on the co-development of tasidotin, a novel dolastatin analogue that has shown efficacy signals and a good safety profile in previous oncology clinical trials.
As part of the agreement, Ergomed will advance the oral formulation of tasidotin, developed by Genzyme, into clinical trials. In an earlier Phase II clinical trial sponsored by Genzyme, the intravenous formulation of tasidotin demonstrated clinical activity in patients with melanoma. Tasidotin's mechanism of action is believed to inhibit cell proliferation by suppressing spindle microtubule dynamics through a reduction of the shortening rate; reduction of the switching frequency from growth to shortening; and reduction of the time microtubules grow.
Other news from the department business & finance
